Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conjugated estrogens/bazedoxifene - Ligand Pharmaceuticals/Pfizer

Drug Profile

Conjugated estrogens/bazedoxifene - Ligand Pharmaceuticals/Pfizer

Alternative Names: Aprela; Bazedoxifene acetate/conjugated estrogens; Bazedoxifene/conjugated estrogens; Bazedoxifene/Premarin®; BZA/CE; CE/BZA; Conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin®/bazedoxifene; SERM + Premarin

Latest Information Update: 22 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Merck Sharp & Dohme; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Azepines; Calcium regulators; Estradiol congeners; Hormonal replacements; Indoles; Osteoporosis therapies; Phenols; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms
  • Phase II Breast cancer

Most Recent Events

  • 22 Jul 2019 Conjugated estrogens/bazedoxifene is not yet available for Postmenopausal osteoporosis in Chile (PO)
  • 22 Jul 2019 Conjugated estrogens/bazedoxifene is not yet available for Vasomotor symptoms in Chile, Canada (PO)
  • 04 Feb 2019 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top